Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 2:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 4,124 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Carcinoma, Small Cell Lung Clear all
Completed Phase 1 Interventional

A Study of ABBV-428, an Immunotherapy, in Subjects With Advanced Solid Tumors

NCT02955251
View directory record Official record
Conditions
Advanced Solid Tumors Cancer
Interventions
ABBV-428, Nivolumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
7
States / cities
Scottsdale, Arizona • Sacramento, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Oct 18, 2026, 2:48 AM EDT
Completed No phase listed Observational

S9925: Collecting and Storing Samples From Patients With Lung Cancer

NCT00920010
View directory record Official record
Conditions
Lung Cancer
Interventions
biologic sample preservation procedure
Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
2,264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2013
U.S. locations
431
States / cities
Mobile, Alabama • Anchorage, Alaska • Tucson, Arizona + 283 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2015 · Synced Oct 18, 2026, 2:48 AM EDT
Completed Phase 2 Interventional Results available

Study of Arsenic Trioxide in Small Cell Lung Cancer

NCT01470248
View directory record Official record
Conditions
Lung Cancer, Cancer of Lung, Pulmonary Cancer, Pulmonary Neoplasms, Carcinoma, Small Cell
Interventions
Arsenic Trioxide
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Oct 18, 2026, 2:48 AM EDT
Active, not recruiting Phase 2 Interventional

Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer

NCT02983578
View directory record Official record
Conditions
Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Carcinoma, Mismatch Repair Deficiency, Refractory Colorectal Carcinoma, Refractory Lung Carcinoma, Refractory Pancreatic Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions
Danvatirsen, Durvalumab
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 18, 2026, 2:48 AM EDT
Completed Phase 3 Interventional Results available

Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer

NCT01107626
View directory record Official record
Conditions
Lung Cancer
Interventions
Paclitaxel, Carboplatin, Bevacizumab, Pemetrexed Disodium Heptahydrate
Drug · Biological
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
1,516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
434
States / cities
Anniston, Alabama • Fairbanks, Alaska • Fairfield, California + 312 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2023 · Synced Oct 18, 2026, 2:48 AM EDT
Completed Phase 1 Interventional

A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface

NCT04752215
View directory record Official record
Conditions
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Carcinoma, Hepatocellular, Head and Neck Neoplasms, Gastrointestinal Neoplasms
Interventions
BI 765049, ezabenlimab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 18, 2026, 2:48 AM EDT
Completed Not applicable Interventional

Sentinel Lymph Node Mapping in Detecting Cancer That Has Spread to Lymph Nodes in Patients With Non-Small Cell Lung Cancer

NCT00089310
View directory record Official record
Conditions
Lung Cancer
Interventions
technetium-99
Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
12
States / cities
Lewes, Delaware • Newark, Delaware • Evanston, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2016 · Synced Oct 18, 2026, 2:48 AM EDT
Terminated Phase 1 Interventional

A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer

NCT03735290
View directory record Official record
Conditions
Carcinoma, Squamous Cell of Head and Neck, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Non-small Cell Lung Cancer
Interventions
ilixadencel, Pembrolizumab
Biological · Drug
Lead sponsor
Mendus
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
5
States / cities
Coral Gables, Florida • Iowa City, Iowa • Louisville, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Oct 18, 2026, 2:48 AM EDT
Terminated Phase 1 Interventional

Study of RO7515629 in Participants With HLA-G Positive Solid Tumors

NCT05769959
View directory record Official record
Conditions
Renal Cell Carcinoma, Non-small Cell Lung Cancer, Pancreatic Adenocarcinoma, Colorectal Cancer, Ovarian Neoplasms
Interventions
RO7515629, tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Denver, Colorado • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Oct 18, 2026, 2:48 AM EDT
Recruiting Phase 3 Interventional

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

NCT04928846
View directory record Official record
Conditions
Non Small Cell Lung Cancer, c-MET
Interventions
Telisotuzumab Vedotin, Docetaxel
Biological · Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
768 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
50
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 18, 2026, 2:48 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Harnessing Allo-immunity to Enhance Immune Checkpoint Inhibitor Responses in Advanced NSCLC

NCT06064279
View directory record Official record
Conditions
Stage IV NSCLC
Interventions
Poly ICLC, IVIG
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 18, 2026, 2:48 AM EDT
Recruiting Phase 1 Interventional

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

NCT06917079
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma, CRC (Colorectal Cancer), Metastatic Non-Small Lung Cell Cancer, Metastatic Colorectal Cancer (CRC), KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12S, KRAS G12V, Metastatic Pancreatic Ductal Adenocarcinoma, Advanced Lung Carcinoma, Solid Tumor, Adult
Interventions
BBO-11818, Pembrolizumab, Platinum chemotherapy (cisplatin or carboplatin), Pemetrexed, Cetuximab, mFOLFOX6, BBO-10203, mFOLFIRINOX, Gemcitabine, Nab-paclitaxel
Drug
Lead sponsor
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Industry
Eligibility
18 Years and older
Enrollment
665 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
16
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 18, 2026, 2:48 AM EDT
Terminated Phase 2 Interventional Results available

Malignant Pleural Effusion With ZD6474

NCT00402896
View directory record Official record
Conditions
Lung Cancer, Pleural Effusion
Interventions
ZD6474
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2016 · Synced Oct 18, 2026, 2:48 AM EDT
Completed Phase 2 Interventional Results available

Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy

NCT04249362
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Durvalumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
Tucson, Arizona • Tampa, Florida • Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 10, 2025 · Synced Oct 18, 2026, 2:48 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) - 1

NCT03743051
View directory record Official record
Conditions
Cachexia; Cancer, Non Small Cell Lung Cancer
Interventions
Anamorelin Hydrochloride, Placebo Oral Tablet
Drug
Lead sponsor
Helsinn Healthcare SA
Industry
Eligibility
18 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
24
States / cities
Tucson, Arizona • Little Rock, Arkansas • Riverside, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 18, 2026, 2:48 AM EDT
Recruiting Phase 2 Interventional

Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer

NCT07250477
View directory record Official record
Conditions
Non-small Cell Lung Cancer Stage IIIC, Non-small Cell Lung Cancer Stage IV, Non Small Cell Lung Cancer, Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Unresectable
Interventions
Systemic (ICI)-based therapy informed by the PROphet CB assay and the CARG-TT assessment., Standard of Care
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
4
States / cities
Chico, California • Marysville, California • Sacramento, California + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 18, 2026, 2:48 AM EDT
Completed Phase 1 Interventional Results available

Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042

NCT03307785
View directory record Official record
Conditions
Neoplasms, Metastatic Cancer, Advanced Cancer, Solid Tumor, Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer Stage IIIB, Non Small Cell Lung Cancer
Interventions
Niraparib, TSR-042, Carboplatin-Paclitaxel, Bevacizumab, TSR-022, Carboplatin-Pemetrexed, Carboplatin-Nab-Paclitaxel
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
8
States / cities
Scottsdale, Arizona • Encinitas, California • San Marcos, California + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Oct 18, 2026, 2:48 AM EDT
Completed Phase 1 Interventional

Suramin and Either Docetaxel or Gemcitabine in Treating Patients With Stage IIIB or Stage IV Platinum-Refractory Non-Small Cell Lung Cancer

NCT00066768
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
suramin, docetaxel, gemcitabine hydrochloride, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Oct 18, 2026, 2:48 AM EDT
Completed Phase 1 Interventional

Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors

NCT00622674
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Pancreatic Cancer, Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cetuximab, bortezomib
Biological · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 2, 2017 · Synced Oct 18, 2026, 2:48 AM EDT
Completed Phase 2 Interventional Results available

A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer

NCT04702880
View directory record Official record
Conditions
Extensive-stage Small Cell Lung Cancer
Interventions
BMS-986012, Carboplatin, Etoposide, Nivolumab
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
8
States / cities
Birmingham, Alabama • Hackensack, New Jersey • Durham, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 18, 2026, 2:48 AM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel

NCT02684461
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Pembrolizumab
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
5
States / cities
Chapel Hill, North Carolina • Raleigh, North Carolina • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2022 · Synced Oct 18, 2026, 2:48 AM EDT
Terminated Phase 2 Interventional Results available

Cetuximab as Therapy for Recurrent Non-Small Cell Lung Cancer Patients Who Have Received Prior Therapy

NCT00694603
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Cetuximab
Drug
Lead sponsor
Lecia V. Sequist
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 6, 2012 · Synced Oct 18, 2026, 2:48 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase I/II Trial of RAD001 Plus Docetaxel in Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer

NCT00406276
View directory record Official record
Conditions
Lung Cancer
Interventions
RAD001, Docetaxel
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 23, 2013 · Synced Oct 18, 2026, 2:48 AM EDT
Terminated Phase 2 Interventional Results available

Zometa Adjuvant Treatment of Malignant Pleural Effusion Due To Non-Small Cell Lung Cancer

NCT01004510
View directory record Official record
Conditions
Malignant Pleural Effusion, Non Small Cell Lung Cancer
Interventions
zoledronic acid
Drug
Lead sponsor
Peter Bushunow MD
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 4, 2012 · Synced Oct 18, 2026, 2:48 AM EDT